Granted Patent
B2
US 12,662,539 · App. 17/384,601 · Granted Jun 23, 2026
Modulation of endoplasmic reticulum aminopeptidase 2 (ERAP2)-mediated immune response
Inventors:
Sahar Gelfman (Tarrytown, NY); Ann Ligocki (Tarrytown, NY); Giovanni Coppola (Tarrytown, NY); Aris Baras (Tarrytown, NY); Arden Moscati (Tarrytown, NY); Eli A. Stahl (Tarrytown, NY); Jack A. Kosmicki (Tarrytown, NY); Manuel Allen Revez Ferreira (Tarrytown, NY); Carmelo Romano (Tarrytown, NY)
Assignee:
Regeneron Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides methods of treating subjects having an immune disorder by administering a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor to the subject, and optionally an Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) agonist or inhibitor and/or an HLA-Aw19 inhibitor, and also provides methods of identifying subjects having an increased risk for developing an MHC-I-opathy.
Claims (11)
1 . A method of treating a subject having Birdshot Chorioretinopathy (BSCR), the method comprising administering to the subject an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor,
wherein the ERAP2 inhibitor comprises an ERAP2 siRNA comprising a sense strand having a nucleotide sequence set forth in one of odd-numbered SEQ ID NOs: 859-2748 and a corresponding antisense strand having a nucleotide sequence set forth in even-numbered SEQ ID NOs: 859-2748; and
wherein the subject has at least one HLA-Aw19 allele.
2 . The method according to claim 1 , wherein the ERAP2 inhibitory nucleic acid molecule comprises an ERAP2 small interfering RNA (siRNA).
3 . The method according to claim 1 , wherein the subject has a plurality of HLA-Aw19 alleles.
4 . The method according to claim 1 , wherein the at least one HLA-Aw19 allele comprises at least one HLA-A*29 allele, at least one HLA-A*30 allele, at least one HLA-A*31 allele, or at least one HLA-A*33 allele.
5 . The method according to claim 1 , wherein the at least one HLA-Aw19 allele comprises at least one HLA-A*29 allele.
6 . The method according to claim 1 , wherein the at least one HLA-Aw19 allele comprises:
i) at least one HLA-A*29 allele and at least one HLA-A*30 allele;
ii) at least one HLA-A*29 allele and at least one HLA-A*31 allele; or
iii) at least one HLA-A*29 allele and at least one HLA-A*33 allele.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 20, 2026
From: GELFMAN, SAHAR; LIGOCKI, ANN; COPPOLA, GIOVANNI; BARAS, ARIS; MOSCATI, ARDEN; STAHL, ELI A.; KOSMICKI, JACK; FERREIRA, MANUEL ALLEN REVEZ; ROMANO, CARMELO
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 074418/0271 →
Continuity (3)
Provisional Application
63056562
· Jul 25, 2020
Provisional Application
63171672
· Apr 7, 2021
References Cited (85)
US 8969254B2
· Reinherz et al.
· 2015
[cited by applicant]
US 9617596B2
· Comabella et al.
· 2017
[cited by applicant]
US 9907833B2
· Conrad
· 2018
[cited by applicant]
US 20120015904A1
· Sharp et al.
· 2012
[cited by applicant]
US 20150141273A1
· Bosch et al.
· 2015
[cited by applicant]
US 20160145687A1
· Kallionpaa et al.
· 2016
[cited by applicant]
US 20170199196A1
· Bosch et al.
· 2017
[cited by applicant]
US 20190076391A1
· Pogue-Geile et al.
· 2019
[cited by applicant]
US 20190136322A1
· Kallionpaa et al.
· 2019
[cited by applicant]
US 20190375842A1
· Drake
· 2019
[cited by applicant]
WO 2012047294
· 2012
[cited by applicant]
WO 2013152001
· 2013
[cited by applicant]
WO 2014171800
· 2014
[cited by applicant]
WO 2017208001
· 2017
[cited by applicant]
WO 202111376
· 2021
[cited by applicant]
WO 2021113805
· 2021
[cited by applicant]
WO 2022026336
· 2022
[cited by applicant]
Babaie et al, Molecule Immunology 121: 7-19, Epub Mar. 2, 2020, IDS # 5, filed on Dec. 21, 2021 (Year: 2020).
[cited by examiner]
Kato et al (J Immunology 143: 3371-3378, 1989 (Year: 1989).
[cited by examiner]
Lopes de Castro et al (mole Immunology 77:193-204, 2016 (Year: 2016).
[cited by examiner]
Gelfman et al (IOVS 62 (14):3 2021) (Year: 2021).
[cited by examiner]
Castro-Santos et al., “ERAPI and HLA-C interaction in inflammatory bowel disease in the Spanish population”, Innate Immunity, 2017, 23(5), pp. 476-481.
[cited by applicant]
Chiaroni-Clarke et al., “Independent confirmation of juvenile idiopathic arthritis genetic risk loci previously identified by immunochip array analysis”, Pediatric Rheumatology, 2014, 12(53), pp. 1-4.
[cited by applicant]
Deddouche-Grass et al., “Discovery and Optimization of a Series of Benzofuran Selective ERAP1 Inhibitors: Biochemical and In Silico Studies”, ACS Med Chem Lett, 2021, 12, pp. 1137-1142.
[cited by applicant]
Franke et al., “Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci”, Nature Genetics, 2010, 42(12), pp. 1118-1126.
[cited by applicant]
Liddle et al., “Targeting the Regulatory Site of ER Aminopeptidase 1 Leads to the Discovery of a Natural Product Modulator of Antigen Presentation”, J Med Chem, 2020, 63(6), pp. 3348-3358.
[cited by applicant]
Weglarz-Tomczak et al., “Discovery of potent and selective inhibitors of human aminopeptidases ERAP1 and ERAP2 by screening libraries of phosphorus-containing amino acid and dipeptide analogues”, Bioorganic and Medicina…
[cited by applicant]
Zervoudi et al., “Rationally designed inhibitor targeting antigentrimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses”, PNAS, 2013, 110(49), pp. 19890-19895.
[cited by applicant]
Van Hout et al., “Exome sequencing and characterization of 49,960 individuals in the UK Biobank”, Nature, 2020, 586(7831), pp. 749-756.
[cited by applicant]
Reid et al., “Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline”, BMC Bioinformatics, 2014, 15(30), pp. 1-11.
[cited by applicant]
Bai et al., “Inference of high resolution HLA types using genome-wide RNA or DNA sequencing reads”, BMC Genomics, 2014, 15(325), pp. 1-16.
[cited by applicant]
Robinson et al., “The IPD-IMGT/HLA Database—New developments in reporting HLA variation”, Hum Immunol, 2016, 77(3), pp. 233-237.
[cited by applicant]
Jia et al., “Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens”, PLOS One, 2013, 8(6), pp. e64683.
[cited by applicant]
Rich et al., “The Type 1 Diabetes Genetics Consortium”, Ann NY Acad Sci, 2006, 1079, pp. 1-8.
[cited by applicant]
Delaneau et al., “Accurate, scalable and integrative haplotype estimation”, Nature Communications, 2019, 10(5436), pp. 1-10.
[cited by applicant]
Das et al., “Next-generation genotype imputation service and methods”, Nat Genet, 2016, 48(10), pp. 1284-1287.
[cited by applicant]
Mbatchou et al., “Computationally efficient whole genome regression for quantitative and binary traits”, BioRxiv, 2020, pp. 1-88.
[cited by applicant]
Zhou et al., “Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies”, Nature Genetics, 2018, 50, pp. 1335-1341.
[cited by applicant]
Purcell et al., “PLINK: a tool set for whole-genome association and population-based linkage analyses”, Am J Hum Genet, 2007, 81(3), pp. 559-575.
[cited by applicant]
Kuiper et al., “A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathy”, Hum Mol Genet, 2014, 23(22), pp. 6081-6087.
[cited by applicant]
Kuiper et al., “Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis”, Hum Mol Genet, 2018, 27(24), pp. 4333-4343.
[cited by applicant]
Paladini et al., “An allelic variant in the intergenic region between ERAP1 and ERAP2 correlates with an inverse expression of the two genes”, Scientific Reports, 2018, 8(10398), pp. 1-10.
[cited by applicant]
Andres et al., “Balancing Selection Maintains a Form of ERAP2 that Undergoes Nonsense-Mediated Decay and Affects Antigen Presentation”, PLOS Genetics, 2010, 6(10), pp. e1001157.
[cited by applicant]
Coulombe-Huntington et al., “Fine-Scale Variation and Genetic Determinants of Alternative Splicing across Individuals”, PLOS Genetics, 2009, 5(12), pp. e1000766.
[cited by applicant]
Sanz-Bravo et al., “Allele-specific Alterations in the Peptidome Underlie the Joint Association of HLA-A*29:02 and Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) with Birdshot Chorioretinopathy”, Mol Cell Proteomics, 20…
[cited by applicant]
Yao et al., “Influence of ERAP1 and ERAP2 gene polymorphisms on disease susceptibility in different populations”, Human Immunology, 2019, 80(5), pp. 325-334.
[cited by applicant]
Evans et al., “Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility”, Nat Genet, 2011, 43(8), pp. 761-767.
[cited by applicant]
Wisniewski et al., “The association of ERAP1 and ERAP2 single nucleotide polymorphisms and their haplotypes with psoriasis vulgaris is dependent on the presence or absence of the HLA-C*06:02 allele and age at disease on…
[cited by applicant]
Strange et al., “A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1”, Nat Genet, 2010, 42(11), pp. 985-990.
[cited by applicant]
Takeuchi et al., “A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers”, Ann Rheum Dis, 2016, 75(12), pp. 2208-2211.
[cited by applicant]
Sanz-Bravo et al., “Ranking the Contribution of Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Polymorphisms to Shaping the HLA-B*27 Peptidome*”, Mol Cell Proteomics, 2018, 17(7), pp. 1…
[cited by applicant]
Guasp et al., “The Behcet's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing”, J Biol Chem, 2017, 292(23), pp. 9680-9689.
[cited by applicant]
Mckenzie et al., “Taxonomic hierarchy of HLA class I allele sequences”, Genes and Immunity, 1999, 1, pp. 120-129.
[cited by applicant]
Maben et al., “Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1”, J Med Chem, 2020, 63, pp. 103-121.
[cited by applicant]
Lopez De Castro, “How ERAP1 and ERAP2 Shape the Peptidomes of Disease-Associated MHC-I Proteins”, Front Immunol, 2018, 9(2463), pp. 1-17.
[cited by applicant]
Worth et al., “Novel Therapeutic Targets in Axial Spondyloarthritis”, Curr Treat Options in Rheum, 2018, 4, pp. 174-182.
[cited by applicant]
Chen et al., “Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis”, Ann Rheum Dis, 2016, 75, pp. 916-923.
[cited by applicant]
Non-Final Office Action dated Apr. 2, 2024 in related U.S. Appl. No. 17/714,717.
[cited by applicant]
Notice of Allowance dated Mar. 26, 2025 in related U.S. Appl. No. 17/714,717.
[cited by applicant]
Notice of Allowance dated Apr. 24, 2025 in related U.S. Appl. No. 17/714,717.
[cited by applicant]
Freitas-Neto et al., “Birdshot retinochoroidopathy review”, Arq Bras Oftalmol, 2015, 78(1), pp. 56-61.
[cited by applicant]
Ferenchak et al., “Antisense Oligonucleotide Therapy for Ophthalmic Conditions”, Seminars in Ophthalmology, 2021, 36(5-6), pp. 452-457.
[cited by applicant]
Hu et al., “Modulation of Gene Expression in the Eye with Antisense Oligonucleotides”, Nucleic Acid Therapeutics, 2023, 33(6), pp. 339-347.
[cited by applicant]
Garanto, “Antisense RNA Design, Delivery, and Analysis”, Methods in Molecular Biology 2434, 2021, Chapter 22, pp. 321-332.
[cited by applicant]
Vazquez-Dominguez et al., “Efficacy, biodistribution and safety comparison of chemically modified antisense oligonucleotides in the retina”, Nucleic Acids Research, 2024, 52, pp. 10447-10463.
[cited by applicant]
Advisory Action dated Oct. 16, 2024 in related U.S. Appl. No. 17/714,717.
[cited by applicant]
Georgiadis et al. “Inhibitiors of ER Aminopeptidase 1 and 2: From Design to Clinical Application”, Current Medicinal Chemistry, 2019, 26(15), pp. 2715-2729.
[cited by applicant]
De Castro et al., “Molecular and pathogenic effects of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in MHC-I-associated inflammatory disorders: Towards a unifying view”, Molecular Immunology, 2016, 77, pp. 193-…
[cited by applicant]
Agrawal et al., “Genetic associations and functional characterization of M1 aminopeptidases and immune-mediated diseases”, Genes and Immunity, 2014, 15(8), pp. 521-527.
[cited by applicant]
Dimopoulou et al., “Variant in ERAP1 promoter region is associated with low expression in a patient with a Behcet-like MHC-I-opathy”, Journal of Human Genetics, 2019, 65(3), pp. 325-335.
[cited by applicant]
Babaie et al., “The roles of ERAP1 and ERAP2 in autoimmunity and cancer immunity: New insights and perspective”, Molecular Immunology, 2020, 121, pp. 7-19.
[cited by applicant]
Kuo et al., “Endoplasmic reticulum aminopeptidase 2 involvement in metastasis of oral cavity squamous cell carcinoma discovered by proteome profiling of primary cancer cells”, Oncotarget, 2017, 8(37), pp. 61698-61708.
[cited by applicant]
Final Office Action dated Aug. 2, 2024 in related U.S. Appl. No. 17/714,717.
[cited by applicant]
Bousquet et al., “Birdshot Chorioretinopathy: A Review”, Journal of Clinical Medicine, 2022, 11(4772), pp. 1-17.
[cited by applicant]
Venema et al., “ERAP2 Increases the Abundance of a Peptide Submotif Highly Selective for the Birdshot Associated HLA-A29”, Front Immunol, 2021, 12(634441), pp. 1-15.
[cited by applicant]